for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Omnicell, Inc.

OMCL.OQ

Latest Trade

143.68USD

Change

-1.61(-1.11%)

Volume

212,428

Today's Range

143.35

 - 

146.39

52 Week Range

62.26

 - 

146.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
145.29
Open
144.25
Volume
212,428
3M AVG Volume
6.17
Today's High
146.39
Today's Low
143.35
52 Week High
146.60
52 Week Low
62.26
Shares Out (MIL)
43.19
Market Cap (MIL)
6,205.53
Forward P/E
39.75
Dividend (Yield %)
--

Next Event

Q2 2021 Omnicell Inc Earnings Release

Latest Developments

More

Omnicell Reports Fiscal Year And Fourth Quarter 2020 Results

Omnicell Inc Sees Fy 2020 Revenue $890 Million To $892 Million

Omnicell Says Q3 Revenue $213.7 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Omnicell, Inc.

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Industry

Software & Programming

Contact Info

590 E Middlefield Rd

MOUNTAIN VIEW, CA

94043-4008

United States

+1.650.2516100

https://www.omnicell.com/

Executive Leadership

Randall A. Lipps

Chairman of the Board, President, Chief Executive Officer

Peter J. Kuipers

Chief Financial Officer, Executive Vice President

Christine Mellon

Chief Human Resource Officer, Executive Vice President

Daniel S. Johnston

Executive Vice President, Chief Legal and Administrative Officer

Scott P. Seidelmann

Executive Vice President and Chief Commercial Officer

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.8K

2019

0.9K

2020

0.9K

2021(E)

1.1K
EPS (USD)

2018

2.090

2019

2.810

2020

2.540

2021(E)

3.615
Price To Earnings (TTM)
184.80
Price To Sales (TTM)
6.79
Price To Book (MRQ)
6.14
Price To Cash Flow (TTM)
62.30
Total Debt To Equity (MRQ)
46.72
LT Debt To Equity (MRQ)
46.72
Return on Investment (TTM)
2.72
Return on Equity (TTM)
2.25

Latest News

Latest News

Baxter in $5 billion bid for Omnicell -sources

Medical supplies provider Baxter International Inc has approached medication management software vendor Omnicell Inc with an offer to acquire it for more than $5 billion, people familiar with the matter said on Tuesday.

BRIEF-Omnicell Says On Feb 12, Received Letter From SEC Confirming That It Has Concluded Its Investigation Related To Co's Accounting Processes & Procedures

* OMNICELL - ON FEBR 12, RECEIVED LETTER FROM SEC CONFIRMING THAT IT HAS CONCLUDED ITS INVESTIGATION RELATED TO CO'S ACCOUNTING PROCESSES & PROCEDURES

BRIEF-Omnicell Inc Says Geisinger Has Partnered With Company

* OMNICELL INC - THROUGH SIX-YEAR SOLE SOURCE AGREEMENT WITH OMNICELL, GEISINGER WILL EMPLOY OMNICELL XT AUTOMATED DISPENSING SYSTEMS Source text for Eikon: Further company coverage:

BRIEF-Omnicell Reports Q4 Non-Gaap Earnings Per Share $0.77

* OMNICELL REPORTS FISCAL YEAR AND FOURTH QUARTER 2019 RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up